Avelumab
Information
- Drug Name
- Avelumab
- Description
- Entry(CIViC)
- 2
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| lung non-small cell carcinoma | CD274 EXPRESSION CD274 EXPRESSION | B |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
4 | 26918451 | Detail |
| lung non-small cell carcinoma | CD274 EXPRESSION CD274 EXPRESSION | B |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
4 | 28472902 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| Meta-Analysis of PD-L1 (CD274) Expression Status i... | CD274 | CD274 EXPRESSION CD274 EXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| In this meta-analysis of 14 studies with 2857 pati... | CD274 | CD274 EXPRESSION CD274 EXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05419362 | Active, not recruiting | Phase 2 | GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer | April 7, 2022 | December 2024 |
| NCT03586869 | Active, not recruiting | Phase 1/Phase 2 | QUILT-3.080: NANT Pancreatic Cancer Vaccine | July 28, 2018 | December 2019 |
| NCT03575013 | Active, not recruiting | Phase 1 | A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer | October 29, 2018 | February 23, 2026 |
| NCT04513951 | Active, not recruiting | Phase 2 | AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients | April 1, 2020 | July 31, 2024 |
| NCT03217747 | Active, not recruiting | Phase 1/Phase 2 | Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies | August 2, 2017 | September 30, 2024 |
| NCT03244176 | Active, not recruiting | Early Phase 1 | Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study | July 21, 2017 | July 2025 |
| NCT03573648 | Active, not recruiting | Phase 2 | Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer | November 13, 2018 | December 31, 2025 |
| NCT04266912 | Active, not recruiting | Phase 1/Phase 2 | Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors | March 17, 2020 | September 11, 2024 |
| NCT03260023 | Active, not recruiting | Phase 1/Phase 2 | Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers | September 11, 2017 | December 2025 |
| NCT03568097 | Active, not recruiting | Phase 2 | Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer | September 16, 2018 | April 2024 |
| NCT04242238 | Active, not recruiting | Phase 1 | Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas | January 22, 2020 | January 22, 2025 |
| NCT03271372 | Active, not recruiting | Phase 3 | Adjuvant Avelumab in Merkel Cell Cancer | December 19, 2017 | February 18, 2029 |
| NCT03563157 | Active, not recruiting | Phase 1/Phase 2 | QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine | May 25, 2018 | December 30, 2022 |
| NCT05366725 | Active, not recruiting | A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy | June 29, 2022 | November 30, 2024 | |
| NCT04215146 | Active, not recruiting | Phase 2 | A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study | June 10, 2020 | July 2024 |
| NCT02999087 | Active, not recruiting | Phase 3 | Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH) | September 14, 2017 | December 2027 |
| NCT03503786 | Active, not recruiting | Phase 2 | Carboplatin, Paclitaxel With or Without Avelumab in Advanced or Recurrent Endometrial Cancer | April 1, 2018 | December 2023 |
| NCT03498378 | Active, not recruiting | Phase 1 | Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | June 6, 2018 | December 2024 |
| NCT03329248 | Active, not recruiting | Phase 1/Phase 2 | QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | November 6, 2017 | December 2020 |
| NCT04173507 | Active, not recruiting | Phase 2 | Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial) | February 14, 2020 | July 1, 2024 |
| NCT03494322 | Active, not recruiting | Phase 2 | EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck Cancer | July 20, 2018 | October 31, 2024 |
| NCT05217069 | Active, not recruiting | Phase 2 | FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC | September 27, 2019 | August 1, 2024 |
| NCT03357757 | Active, not recruiting | Phase 2 | Avelumab With Valproic Acid in Virus-associated Cancer | February 7, 2018 | February 26, 2027 |
| NCT03491345 | Active, not recruiting | Phase 2 | K-Basket, Avelumab, Biomarker-driven, Advanced Solid Tumor | August 1, 2017 | December 2022 |
| NCT03387085 | Active, not recruiting | Phase 1/Phase 2 | QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. | March 16, 2018 | October 2023 |
| NCT03440567 | Active, not recruiting | Phase 1 | Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma | April 2, 2018 | December 30, 2024 |
| NCT03387111 | Active, not recruiting | Phase 1/Phase 2 | QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed | January 13, 2018 | April 2021 |
| NCT04004442 | Active, not recruiting | Phase 1 | Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma | February 17, 2020 | September 2024 |
| NCT04822350 | Active, not recruiting | A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA | July 13, 2021 | June 30, 2024 | |
| NCT03414658 | Active, not recruiting | Phase 2 | The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer | June 21, 2018 | May 31, 2025 |
| NCT04637594 | Active, not recruiting | Phase 3 | Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy | December 10, 2020 | September 2030 |
| NCT03964532 | Active, not recruiting | Phase 1/Phase 2 | TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer | April 17, 2019 | December 2024 |
| NCT03944941 | Active, not recruiting | Phase 2 | Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer | May 17, 2019 | December 2024 |
| NCT03893903 | Active, not recruiting | Phase 1 | AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma | October 19, 2018 | December 2024 |
| NCT03845166 | Active, not recruiting | Phase 1 | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors | March 20, 2019 | November 2024 |
| NCT03186326 | Active, not recruiting | Phase 2 | Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer | April 24, 2018 | May 31, 2023 |
| NCT03826589 | Active, not recruiting | N/A | Avelumab With Axitinib in Persistent or Recurrent Cervical Cancer After Platinum-based Chemotherapy | June 1, 2019 | July 1, 2024 |
| NCT03147287 | Active, not recruiting | Phase 2 | Palbociclib After CDK and Endocrine Therapy (PACE) | September 5, 2017 | December 31, 2024 |
| NCT05092958 | Active, not recruiting | Phase 3 | Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study | June 3, 2022 | December 10, 2024 |
| NCT03815643 | Active, not recruiting | Phase 3 | Avelumab Program Rollover Study | March 22, 2019 | November 1, 2024 |
| NCT04562441 | Active, not recruiting | Phase 2 | NPC - AXEL Study : Axitinib-Avelumab | May 6, 2021 | December 31, 2027 |
| NCT02912572 | Active, not recruiting | Phase 2 | Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer | November 14, 2016 | March 2027 |
| NCT03750071 | Active, not recruiting | Phase 1/Phase 2 | VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma | November 21, 2018 | December 31, 2022 |
| NCT03747484 | Active, not recruiting | Phase 1/Phase 2 | Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer | July 3, 2019 | January 10, 2025 |
| NCT03744793 | Active, not recruiting | Phase 2 | Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer | April 11, 2019 | January 31, 2025 |
| NCT03719768 | Active, not recruiting | Phase 1 | Avelumab With Radiotherapy in Patients With Leptomeningeal Disease | June 10, 2019 | March 1, 2025 |
| NCT03674424 | Active, not recruiting | Phase 2 | Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial) | June 1, 2018 | January 31, 2025 |
| NCT03636503 | Active, not recruiting | Phase 1 | RITUXIMAB + IMMUNOTHERAPY IN FOLLICULAR LYMPHOMA | October 30, 2018 | October 30, 2024 |
| NCT05059522 | Active, not recruiting | Phase 3 | Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | September 29, 2021 | September 30, 2026 |
| NCT03617666 | Active, not recruiting | Phase 2 | Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study | September 27, 2019 | May 30, 2025 |
| NCT03089658 | Approved for marketing | Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC) | |||
| NCT03403777 | Completed | Phase 2 | Avelumab in Refractory Testicular Germ Cell Cancer. | November 15, 2017 | February 28, 2019 |
| NCT02155647 | Completed | Phase 2 | Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200) | July 3, 2014 | May 3, 2023 |
| NCT02395172 | Completed | Phase 3 | Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200) | March 24, 2015 | December 3, 2019 |
| NCT02576574 | Completed | Phase 3 | Avelumab in First-line NSCLC (JAVELIN Lung 100) | October 29, 2015 | January 29, 2024 |
| NCT02580058 | Completed | Phase 3 | A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200) | December 21, 2015 | July 12, 2022 |
| NCT02603432 | Completed | Phase 3 | A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100) | April 25, 2016 | March 28, 2023 |
| NCT02625610 | Completed | Phase 3 | Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) | December 24, 2015 | June 3, 2021 |
| NCT02625623 | Completed | Phase 3 | Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) | December 28, 2015 | November 13, 2019 |
| NCT02859454 | Completed | Phase 2 | Avelumab for People With Recurrent Respiratory Papillomatosis | August 6, 2016 | September 15, 2021 |
| NCT02915523 | Completed | Phase 1/Phase 2 | Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer | December 19, 2016 | April 21, 2021 |
| NCT02938273 | Completed | Phase 1 | Bioimmunoradiotherapy (Cetuximab/RT/Avelumab) | February 1, 2017 | September 30, 2019 |
| NCT02968940 | Completed | Phase 2 | Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma | March 17, 2017 | August 29, 2019 |
| NCT03006848 | Completed | Phase 2 | A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma | February 16, 2017 | March 18, 2020 |
| NCT03046953 | Completed | Phase 2 | Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma | November 14, 2017 | July 27, 2021 |
| NCT03047473 | Completed | Phase 2 | Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme | March 10, 2017 | August 9, 2021 |
| NCT03147404 | Completed | Phase 2 | Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes | December 28, 2017 | July 22, 2019 |
| NCT03152565 | Completed | Phase 1/Phase 2 | Avelumab Plus Autologous Dendritic Cell Vaccine in Pre-treated Metastatic Colorectal Cancer Patients | March 12, 2018 | October 5, 2020 |
| NCT03158883 | Completed | Early Phase 1 | UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients | May 17, 2017 | June 24, 2020 |
| NCT03174405 | Completed | Phase 2 | Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer - The Phase II AVETUX-CRC Trial. | July 17, 2017 | July 16, 2021 |
| NCT03179410 | Completed | Phase 2 | PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer | February 1, 2018 | December 18, 2020 |
| NCT03200587 | Completed | Phase 1 | Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC) | June 21, 2018 | November 25, 2021 |
| NCT03258398 | Completed | Phase 2 | A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer | September 18, 2017 | May 13, 2019 |
| NCT03270176 | Completed | Phase 1 | A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy | October 10, 2017 | March 22, 2022 |
| NCT03278405 | Completed | Phase 1/Phase 2 | Avelumab in G3 NEC | November 15, 2017 | March 12, 2020 |
| NCT03291314 | Completed | Phase 2 | Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma | May 3, 2017 | January 1, 2019 |
| NCT03299660 | Completed | Phase 2 | Avelumab With Chemoradiation in Locally Advanced Rectal Cancer | April 30, 2018 | February 28, 2023 |
| NCT03341806 | Completed | Phase 1 | Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma | June 13, 2018 | October 13, 2021 |
| NCT03352934 | Completed | Phase 2 | Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After Chemotherapy | December 7, 2017 | February 18, 2022 |
| NCT03389126 | Completed | Phase 2 | Phase II Study of Avelumab in Patients With Advanced Hepatocellular Carcinoma After Prior Sorafenib Treatment | December 1, 2017 | January 31, 2020 |
| NCT03390296 | Completed | Phase 1/Phase 2 | OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia | December 27, 2017 | February 4, 2022 |
| NCT03399552 | Completed | Phase 1/Phase 2 | Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma | December 20, 2017 | January 20, 2023 |
| NCT01772004 | Completed | Phase 1 | Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor) | January 31, 2013 | December 16, 2019 |
| NCT03409458 | Completed | Phase 1/Phase 2 | A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab | April 24, 2018 | August 31, 2022 |
| NCT03451825 | Completed | Phase 1 | Phase I/II Study of Avelumab in Pediatric Cancer Subjects | March 7, 2018 | July 27, 2021 |
| NCT03514719 | Completed | Phase 1 | PD-L1 Imaging in Non Small Cell Lung Cancer' (PINNACLE) | October 1, 2018 | December 2, 2021 |
| NCT03558139 | Completed | Phase 1 | Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy | May 23, 2018 | December 3, 2020 |
| NCT03617913 | Completed | Phase 2 | Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer | September 19, 2018 | July 27, 2020 |
| NCT03704467 | Completed | Phase 1 | Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer | March 4, 2019 | November 6, 2019 |
| NCT03717155 | Completed | Phase 2 | Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC | October 30, 2018 | May 27, 2021 |
| NCT03724890 | Completed | Phase 1 | Study of Avelumab-M3814 Combinations | November 27, 2018 | August 17, 2022 |
| NCT03783936 | Completed | Phase 2 | Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas | January 24, 2019 | August 30, 2022 |
| NCT03854799 | Completed | Phase 2 | Immunotherapy In Locally Advanced Rectal Cancer | April 1, 2019 | September 30, 2023 |
| NCT03891238 | Completed | Phase 2 | Avelumab as Single Agent in Metastatic or Locally Advanced Urothelial Cancer in Patients Unfit for Cisplatin. The ARIES Study | February 6, 2019 | September 15, 2021 |
| NCT03892642 | Completed | Phase 1/Phase 2 | Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer | May 1, 2019 | August 13, 2023 |
| NCT03905135 | Completed | Phase 1 | Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies | June 7, 2019 | May 17, 2022 |
| NCT03941262 | Completed | Phase 1 | Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy | July 15, 2019 | February 17, 2023 |
| NCT03990571 | Completed | Phase 2 | Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma | July 22, 2019 | March 20, 2023 |
| NCT04065555 | Completed | Early Phase 1 | Intratumoral Microdosing of TAK-981 in Head and Neck Cancer | October 7, 2020 | July 20, 2022 |
| NCT04068831 | Completed | Phase 2 | Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma | August 22, 2019 | December 6, 2023 |
| NCT04322643 | Completed | Phase 2 | Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma | March 23, 2020 | April 17, 2023 |
| NCT04561336 | Completed | Phase 2 | Avelumab Plus Cetuximab in Pre-treated RAS Wild Type Metastatic Colorectal Cancer | August 10, 2018 | November 14, 2021 |
| NCT04601402 | Completed | Phase 1 | GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy | October 26, 2020 | January 11, 2023 |
| NCT04682587 | Completed | To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma | February 24, 2021 | April 5, 2021 | |
| NCT05012865 | Completed | Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART) | September 14, 2021 | January 31, 2022 | |
| NCT05394493 | Completed | An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK | June 11, 2021 | August 30, 2023 | |
| NCT05431777 | Completed | A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has Spread | July 19, 2022 | January 16, 2023 | |
| NCT05650164 | Completed | Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2) | January 25, 2023 | October 13, 2023 | |
| NCT05700344 | Completed | SOGUG-AVELUMAB_RWD | September 5, 2022 | November 2, 2023 | |
| NCT05687721 | Not yet recruiting | Phase 1/Phase 2 | Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer | July 1, 2024 | December 31, 2028 |
| NCT06424717 | Not yet recruiting | Phase 2 | Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder) | July 29, 2024 | January 27, 2026 |
| NCT06302426 | Not yet recruiting | Phase 1 | Trial of INI-4001 in Patients With Advanced Solid Tumours | March 29, 2024 | April 30, 2026 |
| NCT06204614 | Not yet recruiting | Early Phase 1 | Drug Screening Using IMD in Bladder Cancer | February 14, 2024 | July 1, 2025 |
| NCT04188119 | Not yet recruiting | Phase 2 | A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer | December 1, 2023 | May 31, 2025 |
| NCT03747419 | Recruiting | Phase 2 | Avelumab and Radiation in Muscle-Invasive Bladder Cancer | December 13, 2018 | September 30, 2031 |
| NCT03844763 | Recruiting | Phase 1/Phase 2 | Targeting the Tumor Microenvironment in R/M SCCHN | January 7, 2019 | June 30, 2024 |
| NCT03076554 | Recruiting | Phase 2 | A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy | April 19, 2017 | June 30, 2025 |
| NCT05600127 | Recruiting | Phase 2 | Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer | December 1, 2022 | December 2026 |
| NCT04068194 | Recruiting | Phase 1/Phase 2 | Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies | April 7, 2020 | December 3, 2024 |
| NCT06412848 | Recruiting | JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study | May 9, 2024 | July 31, 2024 | |
| NCT04071236 | Recruiting | Phase 1/Phase 2 | Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy | October 14, 2020 | January 31, 2025 |
| NCT05291156 | Recruiting | Phase 2 | CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy | July 21, 2022 | July 1, 2025 |
| NCT06228066 | Recruiting | Phase 2 | Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER) | June 23, 2024 | September 1, 2028 |
| NCT06225596 | Recruiting | Phase 2/Phase 3 | Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) | January 24, 2024 | December 2030 |
| NCT05081180 | Recruiting | Phase 1 | Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors | December 3, 2021 | December 21, 2025 |
| NCT04261855 | Recruiting | Phase 1/Phase 2 | Targeted Therapy and Avelumab in Merkel Cell Carcinoma | October 8, 2020 | July 2027 |
| NCT05396833 | Recruiting | Phase 1 | Study of M1774 in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320) | June 7, 2022 | May 31, 2026 |
| NCT04291885 | Recruiting | Phase 2 | Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma | October 26, 2020 | April 1, 2028 |
| NCT04341181 | Recruiting | Phase 2 | ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling | August 24, 2020 | April 30, 2025 |
| NCT04360941 | Recruiting | Phase 1 | PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer | August 11, 2020 | December 31, 2025 |
| NCT04387084 | Recruiting | Phase 1 | Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy | August 12, 2020 | August 12, 2025 |
| NCT03547973 | Recruiting | Phase 2 | Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread | August 13, 2018 | July 2026 |
| NCT03774901 | Recruiting | Phase 2 | Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma | March 12, 2019 | September 22, 2024 |
| NCT05327530 | Recruiting | Phase 2 | A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley) | August 17, 2022 | January 23, 2025 |
| NCT03787602 | Recruiting | Phase 1/Phase 2 | Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma | March 19, 2019 | August 2025 |
| NCT03341845 | Recruiting | Phase 2 | Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC | March 28, 2018 | January 31, 2025 |
| NCT05947500 | Recruiting | Phase 2 | Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial | May 21, 2024 | January 1, 2028 |
| NCT04698213 | Recruiting | Phase 2 | Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma | October 7, 2020 | October 2024 |
| NCT04701918 | Recruiting | Phase 2 | Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma | June 4, 2021 | December 2025 |
| NCT04792073 | Recruiting | Phase 2 | Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma | March 8, 2021 | March 2025 |
| NCT03252938 | Recruiting | Phase 1 | Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors | August 15, 2017 | September 30, 2025 |
| NCT04841148 | Recruiting | Phase 2 | Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer | June 1, 2021 | May 2028 |
| NCT04848519 | Recruiting | Phase 2 | Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma | May 20, 2021 | January 1, 2027 |
| NCT04902040 | Recruiting | Phase 1/Phase 2 | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | April 14, 2021 | June 1, 2025 |
| NCT05327686 | Recruiting | Phase 2 | Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study | June 30, 2022 | June 15, 2032 |
| NCT03391479 | Recruiting | Phase 2 | A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy | August 15, 2018 | December 31, 2024 |
| NCT05222932 | Recruiting | Phase 1 | Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1 | March 8, 2023 | December 2026 |
| NCT03971409 | Recruiting | Phase 2 | Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer | July 8, 2019 | June 30, 2025 |
| NCT04871529 | Suspended | Phase 2 | Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL) | August 10, 2022 | April 30, 2029 |
| NCT02718417 | Terminated | Phase 3 | Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) | May 19, 2016 | May 16, 2019 |
| NCT03565991 | Terminated | Phase 2 | Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors | June 18, 2018 | February 3, 2023 |
| NCT03395873 | Terminated | Phase 1 | Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy | January 29, 2018 | May 15, 2019 |
| NCT02603419 | Terminated | Phase 1 | Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS) | March 10, 2016 | April 11, 2019 |
| NCT02584829 | Terminated | Phase 1/Phase 2 | Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma | November 6, 2015 | December 18, 2018 |
| NCT03387098 | Terminated | Phase 1/Phase 2 | QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | December 28, 2017 | January 15, 2019 |
| NCT03481920 | Terminated | Early Phase 1 | A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer | January 10, 2018 | June 10, 2019 |
| NCT03312114 | Terminated | Phase 2 | Anti-PD-L1 and SAbR for Ovarian Cancer | November 9, 2017 | March 19, 2019 |
| NCT03502681 | Terminated | Phase 1 | A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients | June 12, 2018 | October 25, 2019 |
| NCT03324282 | Terminated | Phase 2 | First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder Carcinoma | February 23, 2018 | January 14, 2022 |
| NCT03498196 | Terminated | Phase 1/Phase 2 | A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer | December 14, 2018 | December 9, 2019 |
| NCT03770455 | Terminated | Phase 2 | Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC | January 25, 2019 | January 7, 2021 |
| NCT02554812 | Terminated | Phase 1/Phase 2 | A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) | November 9, 2015 | March 23, 2023 |
| NCT03267836 | Terminated | Phase 1 | Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma | January 10, 2018 | April 6, 2023 |
| NCT05249569 | Terminated | Phase 2 | Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma | November 4, 2022 | December 30, 2022 |
| NCT03136406 | Terminated | Phase 1/Phase 2 | QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | August 11, 2017 | November 1, 2019 |
| NCT03827044 | Terminated | Phase 3 | Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer | August 31, 2018 | January 5, 2022 |
| NCT03853317 | Terminated | Phase 2 | QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy | February 24, 2020 | October 1, 2021 |
| NCT03861403 | Terminated | Phase 1 | A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors | May 20, 2019 | July 14, 2020 |
| NCT05395052 | Terminated | Phase 1 | FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | May 31, 2022 | August 11, 2023 |
| NCT03074318 | Terminated | Phase 1/Phase 2 | Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery | September 28, 2017 | November 15, 2020 |
| NCT02349633 | Terminated | Phase 1/Phase 2 | Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M) | May 14, 2015 | May 28, 2020 |
| NCT03910439 | Terminated | Phase 2 | Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma | October 17, 2019 | November 4, 2020 |
| NCT03915405 | Terminated | Phase 1 | KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer | September 26, 2019 | November 15, 2022 |
| NCT04887831 | Terminated | Phase 2 | Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab | June 4, 2021 | March 1, 2024 |
| NCT03050814 | Terminated | Phase 2 | Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004 | April 5, 2017 | August 25, 2021 |
| NCT03637491 | Terminated | Phase 1/Phase 2 | A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors | August 15, 2018 | February 2, 2021 |
| NCT03050554 | Terminated | Phase 1/Phase 2 | Stereotactic Body Radiation Therapy (SBRT) Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC) | October 26, 2017 | October 7, 2019 |
| NCT05568407 | Terminated | A Study of Avelumab in Real-World Treatment for Patients With Advanced or Metastatic Urothelial Cancer | January 18, 2023 | June 16, 2023 | |
| NCT03386929 | Terminated | Phase 1/Phase 2 | Survival Prolongation by Rationale Innovative Genomics | November 29, 2017 | December 29, 2022 |
| NCT04052204 | Terminated | Phase 1/Phase 2 | Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | December 30, 2019 | September 29, 2020 |
| NCT04150562 | Terminated | Phase 2 | Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma | May 26, 2020 | September 16, 2021 |
| NCT03000179 | Terminated | Phase 2 | Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma | March 3, 2017 | August 3, 2021 |
| NCT02994953 | Terminated | Phase 1 | A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12) | January 31, 2017 | October 8, 2020 |
| NCT02953561 | Terminated | Phase 1/Phase 2 | Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia | February 20, 2017 | September 30, 2019 |
| NCT02952586 | Terminated | Phase 3 | Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100) | November 28, 2016 | August 25, 2020 |
| NCT02951156 | Terminated | Phase 3 | Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) | December 16, 2016 | December 2, 2019 |
| NCT04551885 | Terminated | Phase 1 | FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | September 7, 2020 | August 11, 2023 |
| NCT02875613 | Terminated | Phase 2 | Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer | January 2017 | April 2019 |
| NCT03483883 | Terminated | Phase 1 | Avelumab/Gemcitabine in Sarcomatoid RCC | March 19, 2018 | February 10, 2021 |
| NCT02584634 | Terminated | Phase 1/Phase 2 | Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101) | December 18, 2015 | July 13, 2022 |
| NCT04571632 | Unknown status | Phase 2 | Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors | September 22, 2020 | December 2023 |
| NCT03608046 | Unknown status | Phase 2 | Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer | October 3, 2018 | December 31, 2023 |
| NCT03800953 | Unknown status | Phase 2 | The Ave-CRT Study for Newly Diagnosed Metastatic Esophageal Squamous Cell Carcinoma | March 20, 2019 | December 31, 2023 |
| NCT03812796 | Unknown status | Phase 2 | Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE) | January 11, 2019 | November 30, 2021 |
| NCT03150706 | Unknown status | Phase 2 | Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer | May 22, 2017 | December 31, 2021 |
| NCT03944252 | Unknown status | Phase 2 | Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS) | September 18, 2018 | February 2022 |
| NCT03950362 | Unknown status | Phase 2 | Bladder PREserVation by RadioTherapy and Immunotherapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer | June 15, 2020 | June 15, 2024 |
| NCT03966118 | Unknown status | Phase 2 | Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma | April 1, 2019 | September 2023 |
| NCT04504552 | Unknown status | Phase 2 | Immune Checkpoint Inhibitor In High Risk Oral Premalignant Lesions | July 16, 2020 | March 31, 2024 |
| NCT02767063 | Unknown status | Phase 1/Phase 2 | Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW) | July 2016 | June 2023 |
| NCT03439501 | Unknown status | Phase 2 | Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY] | January 16, 2018 | March 30, 2022 |
| NCT03512834 | Unknown status | Phase 2 | Paclitaxel-Avelumab for Angiosarcoma | June 1, 2018 | May 2023 |
| NCT03278379 | Unknown status | Phase 2 | Avelumab in G2-3 NET | November 15, 2017 | September 20, 2021 |
| NCT03035630 | Withdrawn | Phase 2 | Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma | May 23, 2017 | December 2020 |
| NCT03794596 | Withdrawn | Phase 2 | A Proof of Concept, Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer | September 2019 | February 28, 2021 |
| NCT03167164 | Withdrawn | Phase 1/Phase 2 | QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy | December 2017 | March 2019 |
| NCT03167177 | Withdrawn | Phase 1/Phase 2 | QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy | December 2017 | March 2019 |
| NCT03169738 | Withdrawn | Phase 1/Phase 2 | QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors | February 2018 | March 2019 |
| NCT03169764 | Withdrawn | Phase 1/Phase 2 | QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy | December 2017 | March 2019 |
| NCT03197571 | Withdrawn | Phase 1/Phase 2 | QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy | December 2017 | March 2019 |
| NCT03699384 | Withdrawn | Phase 1/Phase 2 | Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD) | October 3, 2018 | February 18, 2019 |
| NCT03169777 | Withdrawn | Phase 1/Phase 2 | QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC | August 2018 | March 2019 |
| NCT03554109 | Withdrawn | Phase 2 | QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine | September 2018 | December 2021 |
| NCT03647423 | Withdrawn | Phase 1/Phase 2 | QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma. | August 31, 2018 | August 30, 2022 |
| NCT03563144 | Withdrawn | Phase 2 | QUILT-3.088: NANT Pancreatic Cancer Vaccine | August 2018 | December 30, 2019 |
| NCT03574649 | Withdrawn | Phase 2 | QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer | September 2018 | December 30, 2020 |
| NCT03563170 | Withdrawn | Phase 1/Phase 2 | QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine | May 25, 2018 | August 23, 2019 |
| NCT03169790 | Withdrawn | Phase 1/Phase 2 | QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL | December 2017 | March 2019 |
| NCT03175666 | Withdrawn | Phase 1/Phase 2 | QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy | December 2017 | March 2019 |
| NCT05176288 | Withdrawn | Phase 2 | Avelumab, Palbociclib and Axitinib in Advanced RCC | May 31, 2024 | August 31, 2027 |
| NCT03197584 | Withdrawn | Phase 1/Phase 2 | QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy | December 2017 | April 2019 |